Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 20;12(10):1746.
doi: 10.3390/jpm12101746.

Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center

Camilla Nero  1   2 , Simona Duranti  3 , Flavia Giacomini  3 , Angelo Minucci  4 , Luciano Giacò  5 , Alessia Piermattei  6 , Maurizio Genuardi  2   7 , Tina Pasciuto  8 , Andrea Urbani  2   9 , Gennaro Daniele  10 , Domenica Lorusso  1   2 , Raffaele Pignataro  11 , Giampaolo Tortora  2   12 , Nicola Normanno  13 , Giovanni Scambia  1   2
Affiliations

Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center

Camilla Nero et al. J Pers Med. .

Abstract

The implementation of cancer molecular characterization in clinical practice has improved prognostic re-definition, extending the eligibility to a continuously increasing number of targeted treatments. Broad molecular profiling technologies better than organ-based approaches are believed to serve such dynamic purposes. We here present the workflow our institution adopted to run a comprehensive cancer genome profiling in clinical practice. This article describes the workflow designed to make a comprehensive cancer genome profiling program feasible and sustainable in a large-volume referral hospital.

Keywords: bioinformatics; cancer; comprehensive cancer genome profiling; genomics; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CGP journey.
See this image and copyright information in PMC

References

    1. Pritchard D.E., Moeckel F., Villa M.S., Housman L.T., McCarty C.A., McLeod H.L. Strategies for integrating personalized medicine into healthcare practice. Pers. Med. 2017;14:141–152. doi: 10.2217/pme-2016-0064. - DOI - PubMed
    1. Mosele F., Remon J., Mateo J., Westphalen C.B., Barlesi F., Lolkema M.P., Normanno N., Scarpa A., Robson M., Meric-Bernstam F., et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. Ann. Oncolo. 2017;31:1491–1505. doi: 10.1016/j.annonc.2020.07.014. - DOI - PubMed
    1. Mateo J., Steuten L., Aftimos P., André F., Davies M., Garralda E., Geissler J., Husereau D., Martinez-Lopez I., Normanno N., et al. Delivering precision oncology to patients with cancer. Nat. Med. 2022;28:658–665. doi: 10.1038/s41591-022-01717-2. - DOI - PubMed
    1. André F., Ciruelos E., Rubovszky G., Campone M., Loibl S., Rugo H.S., Iwata H., Conte P., Mayer I.A., Kaufman B., et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 2019;380:1929–1940. doi: 10.1056/NEJMoa1813904. - DOI - PubMed
    1. Mok T.S., Carbone D., Hirsch F. IASLC Atlas of EGFR Testing in Lung Cancer. IASLC. 2017. [(accessed on 9 August 2022)]. Available online: https://www.iaslc.org/research-education/publications-resources-guidelin....

LinkOut - more resources